Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy

DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biochem Pharmacol
Main Authors: Zhao, Chong, Chen, Xin, Zang, Dan, Lan, Xiaoying, Liao, Siyan, Yang, Changshan, Zhang, Peiquan, Wu, Jinjie, Li, Xiaofen, Liu, Ningning, Liao, Yuning, Huang, Hongbiao, Shi, Xianping, Jiang, Lili, Liu, Xiuhua, He, Zhimin, Wang, Xuejun, Liu, Jinbao
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5287571/
https://ncbi.nlm.nih.gov/pubmed/27381943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2016.06.019
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares